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Editorial for BJD 
Identifying the knowns and unknowns in eczema treatment 
Linked article: Nankervis et al. What is the evidence-base for atopic eczema treatments? A 
summary of published randomised controlled trials. BJD-2016-0442.R1 
Sara J Brown 
Atopic eczema (atopic dermatitis; eczema1) is a condition very frequently encountered in 
clinical practice, but it can present considerable challenges in providing effective and holistic 
care. The patient perspective is also one of challenge and sometimes frustration with the 
multitude of different treatment options; these may be purchased or prescribed on a trial-
and-error basis because of the lack of substantive evidence of efficacy or inefficacy. Many 
relatively inexpensive and low-risk treatments are used empirically, but the high population 
prevalence of atopic eczema combined with the chronically relapsing nature of this disease 
results in a large cumulative expense of treatment. The economic burden attributable to 
eczema was estimated to be £465 million/year in the UK as long ago as 19962 and in the USA 
a retrospective study in 2002 identified the annual cost of medical services and prescription 
drugs for the treatment of atopic dermatitis/eczema to be between $0.9 billion and $3.8 
billion3. In the light of this economic burden and recent advances in evidence-based 
healthcare it is perhaps surprising that significant gaps in knowledge remain.  
The summary presented by Nankervis et al. in the BJD this month4 represents the result of a 
substantial amount of work conducted by a group from the Centre of Evidence Based 
Dermatology in Nottingham, UK. This well respected team of dermatologists and dermato-
epidemiologists was commissioned by the UK’s National Institute of Health Research (NIHR) 
to perform a comprehensive review to update a summary of evidence for eczema 
treatments that had been published in the year 2000. The NIHR is a UK government-funded 
body and part of the UK’s National Health Service; its purpose is ‘to conduct leading-edge 
research focused on the needs of patients and the public’5. The current work was requested 
and funded by the NIHR to provide an accessible evidence-base for healthcare professionals, 
patients, guideline writers and clinical researchers4.  
The authors have performed a ‘scoping review’ which is a strategy used to investigate a 
broad research question, in this instance the effectiveness of treatments for atopic eczema. 
A scoping review is designed to summarise the current knowledge-base and identify gaps in 
research for future systematic reviews and/or clinical trials6. In this piece of work, owing to a 
very large number of available publications, the review included only systematic reviews and 
randomised controlled trials (RCTs) since, as the authors state, these were likely to offer the 
most unbiased evidence. The review included a very broad range of interventions and 
outcomes, reflecting the diversity within eczema trials, and including patients of all ages. 
Treatments are helpfully categorised according to whether there is: evidence of benefit; 
evidence of no useful benefit; insufficient evidence; or absence of RCT evidence. Whilst a 
scoping review is primarily a qualitative study, trials were also assessed for risk of bias (using 
a Cochrane collaborator’s tool) and inter-individual agreement in the review team was said 
to be ‘good’4.  
The summary demonstrates that over the update period (i.e. 2000-2013 compared to pre-
2000), the greatest increase in RCTs has been in testing emollients, topical 
immunomodulators and other topical treatments; interestingly the numbers of RCTs for 
dietary interventions and systemic treatments have also doubled. The authors highlight the 
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proactive use of twice-weekly topical corticosteroids or calcineurin inhibitors to maintain 
eczema remission7 as a noteworthy addition and useful strategy in caring for patients with 
moderate-severe eczema. Equally important evidence that should prompt consideration of a 
change in clinical practice is the list of interventions for which there is ‘reasonable evidence 
of no benefit in treating eczema’. This list includes: twice-daily as opposed to once-daily 
topical corticosteroids; antibiotic-containing corticosteroids for non-infected eczema; 
probiotics and dietary supplements for treating eczema; and ion-exchange water softeners 
for moderate-severe atopic eczema4. 
However, despite a very thorough search of the research literature, the review sheds light 
on a field in which some findings are disappointing to say the least. The reporting of trials is 
said to be ‘generally poor’ and only 8% (22/287) of RCTs were defined by the team as having 
low risk of bias in randomisation, allocation concealment and blinding4. However it should 
also be bourn in mind that dermatological research presents some specific challenges in the 
blinding of participants and complex treatments, such as educational interventions, cannot 
effectively be concealed. In total 193 trials including more than 13,500 participants had been 
conducted to investigate treatments for which it is concluded that more research is 
required; a preponderance of small, poorly conducted trials is likely to have contributed to 
this waste of valuable resources. Lastly, there is a notable lack of RCTs conducted in primary 
care, despite evidence of clinical need in this setting. 
It may be surprising to some readers to note that there is currently no RCT evidence for 
commonly used interventions including zinc or ichthammol medicated bandages. 
Furthermore, interventions that may appear to be common sense, e.g. soap avoidance, are 
also currently unproven by the very focussed methodology of RCT. The authors call for 
further, well-designed and adequately powered RCTs as the gold standard with which to 
assess these interventions and treatments. However, given the significant cost implications 
of undertaking what are likely to need to be large clinical trials, a detailed health economic 
assessment is warranted8 to assess the balance of value, both financially and clinically, in 
further investigating these widely used empirical interventions. 
The authors’ entire review is freely available as an NIHR web-resource9 and this includes 
important additional information on the dangers/drawbacks associated with some 
treatments. In addition, the Nottingham group have produced a publically-available online 
resource, the GREAT database (Global Resource of EczemA Trials)10 which they plan to 
update ‘to provide a comprehensive, easy to use resource that contains summary 
information about systematic reviews and randomised controlled trials of eczema 
treatments in order to facilitate the identification of published eczema research and to 
speed up future eczema research projects’ 10.  
The scoping review and accompanying GREAT database are relevant for practicing clinicians 
and should provide a valuable starting-point for any researcher considering performing a 
clinical trial in the treatment of atopic eczema. It will also be a powerful resource for clinical 
guideline-writers. Important gaps in knowledge have been highlighted for further work and 
we should all be mindful of the need for rigorous, carefully designed, adequately powered 
RCTs (where appropriate) to avoid future waste in research11. 
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